Ankylosing Spondylitis and Psoriatic Arthritis PatientsNCT07507487
TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity
A study testing Detection of TNFAIP3 gene expression by real time PCR. in people with Ankylosing Spondylitis and Psoriatic Arthritis Patients, run by Asmaa Hassan mohamed Abdel Mawjoud.
Trial summary
1. Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients. 2. Detect relation between TNFAIP3 and disease activity. Inclusion criteria: 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10). 2. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Ankylosing Spondylitis and Psoriatic Arthritis Patients
- What is being tested?
- Detection of TNFAIP3 gene expression by real time PCR.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 110 participants
- Where
- No sites listed yet
- Study dates
- Apr 2026to Jul 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984.
- 2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010)
Who cannot join
- Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
- Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients.
- Detect relation between TNFAIP3 and disease activity.
Inclusion criteria:
- Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10).
- Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11).
- Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.
- Being tested
- Detection of TNFAIP3 gene expression by real time PCR.
- Medical subject headings
- Spondylitis, Ankylosing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Detection of TNFAIP3 gene expression by real time PCR.Diagnostic test
Detection of TNFAIP3 gene expression by real time PCR.
| Study group | Role | What they receive |
|---|---|---|
| ankylosing spondylitis | Experimental | Not described Receives: Diagnostic Test: Detection of TNFAIP3 gene expression by real time PCR. |
| psoriatic arthritis patients | Experimental | Not described Receives: Diagnostic Test: Detection of TNFAIP3 gene expression by real time PCR. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection of TNFAIP3 gene expression. Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial bone and sacroiliac joints. Its etiology involves genetic, environmental variables and demographic factors .
Measured: 18 months
Secondary outcomes (1)
Detect relation between TNFAIP3 and ankylosing spondylitis apsoriatic arthritis activity. detection of TNFAIP3 gene expression by real time PCR will be done for every subject.
Measured: 20 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2026
- Study startApr 2026 (estimated)
- Primary completionDec 2028 (estimated)
- Study completionJul 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ankylosing Spondylitis and Psoriatic Arthritis PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 110 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Asmaa Hassan mohamed Abdel Mawjoud
- Sponsor type
- University, hospital or other
- Collaborators
- Assiut University
- Responsible party
- Sponsor-investigator, Asmaa Hassan mohamed Abdel Mawjoud, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07507487
- Sponsor's protocol ID
- TNFAIP3 gene expression
- Status last verified
- Mar 2026
- First submitted
- 16 Mar 2026
- Last updated
- 2 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity
- ClinicalTrials.gov ID
- NCT07507487
- Acronym / sponsor ID
- TNFAIP3 gene expression
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 110 participants (estimated)
- Lead sponsor
- Asmaa Hassan mohamed Abdel MawjoudUniversity, hospital or other
- Collaborators
- Assiut University
- Study start
- Apr 2026 (estimated)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Jul 2029 (estimated)
- First posted
- 2 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients.
- Detect relation between TNFAIP3 and disease activity.
Inclusion criteria:
- Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10).
- Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11).
- Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ankylosing spondylitis | Experimental | Diagnostic Test: Detection of TNFAIP3 gene expression by real time PCR. |
| psoriatic arthritis patients | Experimental | Diagnostic Test: Detection of TNFAIP3 gene expression by real time PCR. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984.
- 2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010)
Key exclusion criteria (1 listed)
- Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Detection of TNFAIP3 gene expression by real time PCR.Detection of TNFAIP3 gene expression by real time PCR. | Diagnostic test | ankylosing spondylitis, psoriatic arthritis patients |
Primary outcome
Detection of TNFAIP3 gene expression. Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial bone and sacroiliac joints. Its etiology involves genetic, environmental variables and demographic factors .
Time frame: 18 months
1 secondary outcome
Detect relation between TNFAIP3 and ankylosing spondylitis apsoriatic arthritis activity. detection of TNFAIP3 gene expression by real time PCR will be done for every subject.
Time frame: 20 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Ankylosing Spondylitis and Psoriatic Arthritis Patients
RecruitingObservational study
Identification of Serum Level of Glutathione Peroxidase 4
Spondyloarthropathy
Not yet recruitingObservational study
Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients
Meibomian Gland Dysfunction, Dry Eye Syndromes
Not yet recruitingObservational study
Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Ankylosing Spondylitis, Psoriasis
RecruitingPhase 2
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Rheumatic Disease
RecruitingObservational study
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Ankylosing Spondylitis, Autoimmune Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Detection of TNFAIP3 gene expression by real time PCR. in people with Ankylosing Spondylitis and Psoriatic Arthritis Patients, run by Asmaa Hassan mohamed Abdel Mawjoud.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact asmaa mohmed, master (01024850070, a94asmaa@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection of TNFAIP3 gene expression. Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial bone and sacroiliac joints. Its etiology involves genetic, environmental variables and demographic factors . (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.